ResearcherInstituto Carlos ChagasActive in the last 2 years
Anelis Maria Marin
Matched on ORCID iD 0000-0003-2260-7949; OpenAlex author ID A5045764645. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers
Papers 6
- Detection of mutated KRAS, TP53, CDKN2A, and SMAD4 in tumor cell-free DNA of Brazilian pancreatic adenocarcinoma patients using next-generation sequencing. Co-author DOI 10.1038/s41598-026-42403-4↗
- miRNA484 and miRNA335-5p as Potential Diagnostic Biomarkers for CA19-9-Negative Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/biom16081160↗
- Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer. Co-author DOI 10.3390/biomedicines11041069↗
- Screening of Exosome-Derived Proteins and Their Potential as Biomarkers in Diagnostic and Prognostic for Pancreatic Cancer. Co-author DOI 10.3390/ijms241612604↗
- Plasma Exosome-Derived microRNAs as Potential Diagnostic and Prognostic Biomarkers in Brazilian Pancreatic Cancer Patients. Co-author DOI 10.3390/biom12060769↗
- Susceptibility loci for pancreatic cancer in the Brazilian population. Co-author DOI 10.1186/s12920-021-00956-5↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mateus Nóbrega Aoki · 6 shared papers, 2021–2026 · strength 1.27
- Paper miRNA484 and miRNA335-5p as Potential Diagnostic Biomarkers for CA19-9-Negative Pancreatic Ductal Adenocarcinoma. DOI 10.3390/biom16081160↗
- Paper Detection of mutated KRAS, TP53, CDKN2A, and SMAD4 in tumor cell-free DNA of Brazilian pancreatic adenocarcinoma patien… DOI 10.1038/s41598-026-42403-4↗
- Paper Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer. DOI 10.3390/biomedicines11041069↗
- Guilherme Naccache Namur · 2 shared papers, 2023–2026 · strength 0.49
- Federico Canzian · 2 shared papers, 2021–2026 · strength 0.41
- Nayra Oliveira Prado · 1 shared paper, 2026 · strength 0.29
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.